Home Cart Sign in  
Chemical Structure| 69843-13-6 Chemical Structure| 69843-13-6

Structure of 69843-13-6

Chemical Structure| 69843-13-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 69843-13-6 ]

CAS No. :69843-13-6
Formula : C4H7N3
M.W : 97.12
SMILES Code : NC1=CN(C)N=C1
MDL No. :MFCD05667135
InChI Key :LBGSWBJURUFGLR-UHFFFAOYSA-N
Pubchem ID :4770990

Safety of [ 69843-13-6 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 69843-13-6 ] Show Less

Physicochemical Properties

Num. heavy atoms 7
Num. arom. heavy atoms 5
Fraction Csp3 0.25
Num. rotatable bonds 0
Num. H-bond acceptors 1.0
Num. H-bond donors 1.0
Molar Refractivity 27.89
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

43.84 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

0.88
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

-0.45
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

0.01
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

-0.68
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-0.26
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

-0.1

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-0.69
Solubility 20.0 mg/ml ; 0.205 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

0.0
Solubility 96.0 mg/ml ; 0.989 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-0.35
Solubility 43.0 mg/ml ; 0.443 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

No
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-7.21 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

2.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.29

Application In Synthesis of [ 69843-13-6 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 69843-13-6 ]

[ 69843-13-6 ] Synthesis Path-Downstream   1~3

  • 1
  • [ 944709-42-6 ]
  • [ 69843-13-6 ]
  • 6-bromo-N-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-amine [ No CAS ]
YieldReaction ConditionsOperation in experiment
76% To amixthxe of NaIl (0264 g, &F?4 35 nol) inTEF (50 nL)was added l-methyl-lH-pyrazd-4- amine (2Q97 g, 21.59 nunol). The niixiui was sthmd thrabc?at0.5 hat thc?at 0 C. A so1niiciof (5 g, 17S9 nunDl7 Aik Plmnn) iii TEF C30 iuL)was added slowlyardtlE leacthnnuetnewas siinedforlkat0t. Water(SmL)was a&Ied.Themixtur? was conetted to drjne. Adth&nal two reaction nuethrEs weze set up follcwing the above nitIiri1. All tluee batches were contimd, wa±er (109 mL) was added. The nuetm was extaDted with ECAc (3 x 5J0 niL).The orgaiiic pluse wa diied over NaSOi, comeitated urder iethixed piessuxe, parified ?ue silica gel ci ntognphyebath with 2S5]percent ECAc WE to give Cbvm9-N (J-ty1-SH-pwcroy1flL24]mo[L5-Q1yrc8-ani (12 g, 7A) as a wlite solid: ?H NMR (411 MH; DMSO-D6) 8 ppxw5 10.71 (s, 1H), 8.59-8.56 (d, J 12, 2H), 8i]7 (s, lii), 7.76 (, 1ff), 3.&5 (s, 3H).
  • 2
  • [ 6296-99-7 ]
  • [ 69843-13-6 ]
  • [ 530-62-1 ]
  • diethyl 2-((3-(1-methyl-1H-pyrazol-4-yl)ureido)methylene)malonate [ No CAS ]
YieldReaction ConditionsOperation in experiment
66% Step 1. Diethyl 2-((3-(1-methyl-1H-pyrazol-4-yl)ureido)methylene)malonate A mixture of 1-methyl-1H-pyrazol-4-amine (0.097 g, 1.0 mmol) and 1,1'-carbonyldiimidazole (0.178 g, 1.100 mmol) in DMSO (1 mL) was stirred at rt for 1 h, then diethyl 2-(aminomethylene)malonate (0.187 g, 1.00 mmol) was added to the solution. The reaction mixture was stirred at 80° C. overnight, cooled to rt, and directly purified via column chromatography (0percent to 100percent EtOAc in hexanes) to afford the product (0.204 g, 66percent). LCMS calcd for C13H19N4O5 (M+H)+: m/z=311.1. Found: 311.2.
  • 3
  • [ 68947-43-3 ]
  • [ 69843-13-6 ]
  • 1-methyl-N-(1-methylpyrazol-4-yl)piperidine-4-carboxamide [ No CAS ]
YieldReaction ConditionsOperation in experiment
With pyridine; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; at 0 - 20℃; for 2h;Inert atmosphere; To a mixture of 1 -methylpyrazol-4-amine (0.30 g, 3.09 mmol, 1 eq.) and 1 -methylpiperidine-4-carboxylic acid (442 mg, 3.09 mmol, 1 eq.) in pyridine (10 ml) was added 1 -ethyl-3 -(3- dimethylaminopropyl)carbodiimide hydrochloride (888 mg, 4.64 mmol, 1.5 eq.) in one portion at 0 °C under N2. The mixture was stirred at rt for 2 h. The mixture was concentrated in vacuo then diluted with water (10 ml). The aqueous phase was extracted with ethyl acetate (3 x 10 ml). The combined organic phase was washed with saturated brine (3 x 8 ml), dried over anhydrous Na2S04, filtered and concentrated in vacuo. The residue was purified by silica gel (1022) chromatography (10 - 50 percent MeOH in ethyl acetate) to give 1 -methyl-N-( 1 -methylpyrazol-4- yl)piperidine-4-carboxamide as a white solid. 'H NMR (400 MHz, DMSO-de) d = 9.83 (s, 1H), 7.90 - 7.78 (m, 1H), 7.82 (s, 1H), 7.44 - 7.29 (m, 1H), 5.89 - 5.70 (m, 1H), 3.75 (s, 2H), 3.02 - 2.93 (m, 1H), 3.02 - 2.93 (m, 1H), 2.78 (d, J=\2 Hz, 2H), 2.10 (s, 3H), 1.90 - 1.78 (m, 2H), 1.49- 1.45 (m,lH).
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 69843-13-6 ]

Amines

Chemical Structure| 1063734-49-5

A114149 [1063734-49-5]

1-Methyl-1H-pyrazol-4-amine dihydrochloride

Similarity: 0.97

Chemical Structure| 127107-23-7

A247043 [127107-23-7]

1-Methyl-1H-pyrazol-4-amine hydrochloride

Similarity: 0.97

Chemical Structure| 1896159-87-7

A759680 [1896159-87-7]

N,1-Dimethyl-1H-pyrazol-4-amine dihydrochloride

Similarity: 0.93

Chemical Structure| 28466-26-4

A159049 [28466-26-4]

4-Aminopyrazole

Similarity: 0.84

Chemical Structure| 64517-88-0

A190541 [64517-88-0]

1,3-Dimethyl-1H-pyrazol-4-amine

Similarity: 0.82

Related Parent Nucleus of
[ 69843-13-6 ]

Pyrazoles

Chemical Structure| 1063734-49-5

A114149 [1063734-49-5]

1-Methyl-1H-pyrazol-4-amine dihydrochloride

Similarity: 0.97

Chemical Structure| 127107-23-7

A247043 [127107-23-7]

1-Methyl-1H-pyrazol-4-amine hydrochloride

Similarity: 0.97

Chemical Structure| 1896159-87-7

A759680 [1896159-87-7]

N,1-Dimethyl-1H-pyrazol-4-amine dihydrochloride

Similarity: 0.93

Chemical Structure| 28466-26-4

A159049 [28466-26-4]

4-Aminopyrazole

Similarity: 0.84

Chemical Structure| 64517-88-0

A190541 [64517-88-0]

1,3-Dimethyl-1H-pyrazol-4-amine

Similarity: 0.82